Drug Profile
Research programme: inositol trisphosphate receptor antagonists - Sosei Heptares/Tokyo University
Alternative Names: Research programme: IP3 receptor antagonists - Sosei Heptares/Tokyo UniversityLatest Information Update: 13 Dec 2018
Price :
$50
*
At a glance
- Originator Sosei; University of Tokyo
- Class
- Mechanism of Action Inositol 1,4,5 trisphosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis; Atopic dermatitis
Most Recent Events
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
- 14 Nov 2002 No development reported - Preclinical for Allergic asthma in Japan (unspecified route)
- 14 Nov 2002 No development reported - Preclinical for Allergic rhinitis in Japan (unspecified route)